Inactive Instrument

Epigenomics AG Stock price Xetra

Equities

DE000A1K0516

Biotechnology & Medical Research

End-of-day quote Xetra
- EUR 0.00% Intraday chart for Epigenomics AG
Sales 2024 * 150K 162K Sales 2025 * - Capitalization 1.62M 1.74M
Net income 2024 * - 0 Net income 2025 * - 0 EV / Sales 2024 * -3.47 x
Net cash position 2024 * 2.14M 2.3M Net cash position 2025 * 1.69M 1.82M EV / Sales 2025 * -
P/E ratio 2024 *
-2.77 x
P/E ratio 2025 *
-2.79 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.43%
More Fundamentals * Assessed data
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock Epigenomics AG
  4. Stock Epigenomics AG - Xetra